

Poster presentation

Agmatine synthesis in morphine dependence

Feyza Aricioglu*¹ and Soundar Regunathan²

Address: ¹Marmara University, Department of Pharmacology, Turkey and ²University of Mississippi, USA

* Corresponding author

from International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour
Thessaloniki, Greece. 17–20 November 2005

Published: 28 February 2006

Annals of General Psychiatry 2006, **5**(Suppl 1):S102 doi:10.1186/1744-859X-5-S1-S102

Background

Agmatine is an endogenous amine derived from the decarboxylation of arginine decarboxylase. It has been found in various mammalian organs and is thought to act as a neurotransmitter or neuromodulatory agent. When exogenously administered to rodents, agmatine enhances morphine analgesia, blocks tolerance to opioids and attenuates withdrawal syndrome in morphine.

Materials and methods

Rats were implanted with two morphine pellets (75 mg each) or control placebo pellets. After 24 or 48 hours later animals were sacrificed and brain regions were dissected. Arginine Decarboxylase (ADC) activity was measured by using radioimmunoassay.

Results

ADC activity was found in ventral tegmental area, hypothalamus, cortex, nucleus accumbens, substantia nigra, locus coeruleus, medulla and cerebellum, in order of highest to lowest activity. Exposure of rats to morphine for 24 hours significantly increased ADC activity in hypothalamus, cortex, locus coeruleus, nucleus accumbens and cerebellum, compared to placebo control rats. The change in ventral tegmental area, medulla and substantia nigra were not significantly different. When ADC activity was measured after 72 hours, activity was significantly reduced in all regions that showed an increase after 24 hours.

Discussion

The biosynthesis of agmatine could be increased in specific brain regions during the early phase of morphine exposure as a protective mechanism against dependence and that increasing endogenous agmatine may be beneficial in opiate drug abuse.